Last reviewed · How we verify
ch-mAb7f9
At a glance
| Generic name | ch-mAb7f9 |
|---|---|
| Sponsor | InterveXion Therapeutics, LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, and Pharmacokinetics of IXT-m200 (PHASE1)
- Study of Antibody for Methamphetamine Outpatient Therapy (PHASE1, PHASE2)
- Safety Study of Ch-mAb7F9 for Methamphetamine Abuse (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ch-mAb7f9 CI brief — competitive landscape report
- ch-mAb7f9 updates RSS · CI watch RSS
- InterveXion Therapeutics, LLC portfolio CI